PHOTOREACTIVE GOLD SURFACE--STREPTAVIDIN BASED BIOSENSOR

该项目是为试剂和涂料的开发而设计的 性价比高、功能优越的薄膜技术 生物传感器贵金属表面涂层及其诊断 颗粒(例如，胶体金)。光亲和固定化 链霉亲和素单分子膜结合蛋白的研究 未经事先提纯的原始原料，将被 用两亲性间隔物上的亲水光致基团完成 用一段短的亲水片段连接到疏水的 烷基二硫醇链段。将使用的模型生物传感器系统是 表面等离子激元共振--一种不需要 样品加工，并使用一次性镀金光学塑料 用于现场快速诊断心肌梗死的药盒 急诊室。第一阶段工作的具体目标包括 用于在黄金表面涂覆以稳定地从原油中固定的试剂 来源：一批具有生物素结合能力的链霉亲和素 每平方厘米至少1微克分子，这是稳定的 在实验室环境条件下保存至少3个月，并且 具有特定的分析物结合信号，至少是 它的非特异性结合信号来自血液。后续发展 目标包括-将以下功能提高五倍 特性和多分析物分析能力通过 生物分子在钝化贵金属表面的图案化固定 生物传感器表面。 建议的商业应用商业应用包括 表面等离子体共振(SPR)等贵金属生物传感器 和声表面波(SAW)系统现在市场上或更低 开发/FDA批准用于血栓形成的快速现场诊断 和传染病。仅心脏标记物市场就可能是 据估计，每年有400-500万名患者入院 胸口痛。

This project is designed for the development of reagents and coating technology for cost-effective and functionally superior thin film coating of noble metal surfaces on biosensors and diagnostic particles (e.g., colloidal gold). Photoaffinity immobilization of a monolayer of the "universal binding protein" streptavidin from its crude source material without prior purification, will be accomplished with hydrophilic photogroups on amphophilic spacers with a short hydrophilic segment joined to a hydrophobic alkyldithiol segment. The model biosensor system to be used is Surface Plasmon Resonance, a sensitive optical system requiring no sample processing, and using disposable gold-coated optical plastic cartridges for rapid myocardial infarct diagnosis on site in the emergency room. Specific aims of the Phase I effort include a reagent for coating a gold surface to stably immobilize from crude source solution a load of streptavidin with biotin-binding capacity of at least 1 pmole per square centimeter, which is stable to storage at ambient lab conditions for at least 3 months and which has a specific analyte binding signal at least four times that of its nonspecific binding signal from blood. Subsequent development goals include-a five-fold improvement in these functional characteristics and a multianalyte assay capability through patterned immobilization of biomolecules on passivated noble metal biosensor surfaces. PROPOSED COMMERCIAL APPLICATIONS Commercial applications include the noble metal-based biosensors such as Surface Plasmon Resonance (SPR) and Surface Acoustic Wave (SAW) systems now on the market or under development/FDA approval for rapid, on-site diagnosis of thrombotic and infectious diseases. The cardiac marker market alone may be estimated from the 4-5 million patient admissions each year for chest pains.